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Abstract
Background: Vincristine (VCR), an antineoplastic agent, is a key component in the treatment of acute lymphoblastic
leukemia, lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor diseases. Recently, high incidence of
hyperlipidemia was reported to be associated with allogenic hematopoietic stem cell transplantation and VCR/L-
asparaginase therapy.
The aim of this study is to test the effects of incremental increase in lipoproteins levels on vincristine disposition in rat.
Method: To study VCR pharmacokinetics and protein binding, rats (n = 25) were assigned to three groups, normal
lipidemic (NL), intermediate (IHL) and extreme hyperlipidemic (HL). Hyperlipidemia was induced by ip injection of (1 g/Kg)
poloxamer 407 in rats. Serial blood samples were collected using the pre-inserted jugular vein cannula for 72 h post VCR
(0.15 mg/Kg) i.v. dose. VCR unbound fractions in NL, IHL and HL plasma were determined using ultrafiltration kits.
Results: VCR demonstrated a rapid distribution phase (6–8 h) followed by a slower elimination phase with a mean
elimination t½ of ~ 14 h. VCR exhibited moderate binding to plasma proteins ~ 83 %. It showed a relatively small Vc
(~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicating good tissue distribution. As the lipoproteins levels were increased,
no significant changes were noted in VCR unbound fraction, plasma concentration, or volume of distribution indicating
low affinity to lipoprotein binding. Induced HL also did not affect VCR elimination where similar VCR AUC0-∞, Cl and
elimination phase t½ were reported along the different lipemic groups.
Conclusion: Incremental increase in lipoprotein levels resulted in no significant effect on VCR disposition as such ALL
malignant lymphoma and allogenic hematopoietic stem cell transplantation patients need not to worry about HL-VCR
interaction. Whether, HL can potentiate another drug-drug or drug-disease interaction involving VCR warrants further
studying and monitoring to ensure therapeutic safety and efficiency.
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Background
Acute lymphoblastic leukemia (ALL), characterized by
immature lymphoid cells in the bone marrow, peripheral
blood and other organs, has a high incidence in USA and
worldwide [1]. It affects children and adults with median
diagnosis age of 14 years [1]. ALL treatment show higher
cure rates in children than adults and involves a complex
and intensive therapy program. Said R et al. [1] vincristine
(VCR) is an antineoplastic agent that acts by inhibiting
microtubule formation in the miotic spindle causing cell
death that may be accompanied by neurological side effect
[2, 3]. It represents a key component in the ALL in
children and adults and is currently the backbone of
the induction, intensification, and consolidation phases
in the treatment of this disease [4]. VCR is also used in
combination with other oncolytic drugs for the treatment of
Hodgkin’s disease, non–Hodgkin’s malignant lymphomas,
rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor [5].
VCR clinical efficacy is significantly dependent on its
concentration and duration of exposure [1]. Unfortu-
nately, it carries the potential for neurological toxicity
that is both dose and duration dependent and is charac-
terized by neuropathy, paresthesia, sensory deficits, muscle
weakness, and rarely seizures [3, 6]. Hence, minimal al-
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serious consequences on its efficacy as well as its
neurotoxicity.
After VCR intravenous injection, it is metabolized by
liver CYP3A (mainly CYP3A4 and CYP3A5) and elimi-
nated mainly in the bile with a low proportion excreted
in the urine (about 8 to 15 %) [1, 3, 7] VCR reported
clinical PK data showed a wide range of difference in the
elimination phase t½ (range 155–5100 min), volume of
distribution (Vβ) (range 57–420 L/m
2) and clearance
(range 82–482 mL/min/m2) among tested patients [1]. It
has linear low affinity binding to plasma proteins, mostly
AAG, with a reported unbound fraction of 0.5 [7]. Gen-
erally, VCR has a short distribution t½, large volume of
distribution and long elimination phase t½ suggesting a
high capacity to normal tissue binding which may result
in limited tumor tissue exposure in vivo [1]. VCR also
demonstrated high accumulation in most organs and tis-
sues except the brain, eye and fat [1]. In rodents, VCR
exhibited similar PK pattern where it was reported to
have a biphasic plasma drug concentration decay patterns
with a rapid distribution phase t½ ranging between 42–
73 min followed by a slower elimination phase t½ of
14.3 ± 6.3 h. it showed a relatively large volume of dis-
tribution and a clearance of 0.12 ± 0.08 L/h/Kg [8].
Hyperlipidemia (HL) is a common pathological condi-
tion characterized by an abnormal elevation of plasma li-
poproteins [9–11]. It is either caused by a defect in the
genetic makeup or secondarily to other factors including
diet, sedentary lifestyle habits, and certain drugs or dis-
eases [12]. Worldwide increases in diabetes and obesity
have increased the HL incidence in the last few years
[9, 12]. A condition that poses an important clinical
concern due to the sustained increases in low-density
lipoprotein (LDL) that is a direct contributor to an in-
creased risk of atherosclerosis, hypertension and ischemic
heart disease [13, 14]. In addition, recent publications have
clearly demonstrated the effect of HL on pharmacokinet-
ics, pharmacodynamics and toxicodynamics of some drugs
[11, 15–18]. This is owing to either reduced unbound
fraction, altered metabolizing enzymes expression and/or
enhanced lipoprotein receptor–mediated drug tissue
uptake [11, 12, 16].
Recent reports have demonstrated a high incidence of
HL in the first two years after allogenic hematopoietic
stem cell transplantation [19]. In addition acute and se-
vere hypertriglyceridemia (>10,000 mg/L of plasma tri-
glyceride concentration) was shown to be associated with
VCR/L-asparaginase treatment of ALL and malignant
lymphoma patients [20]. This was suggested to be due
to higher frequency of the apoE4/E3 phenotype in the
patients with extreme hypertriglyceridemia as well as
an increase in the apoCIII/apoCII ratio that results in
inhibition of lipoprotein lipase enzyme leading to an ac-
cumulation of triglyceride-rich lipoproteins in plasma.
Whether a potential interaction between VCR and HL
exists is still unknown, however, a study of this inter-
action is crucial considering that HL has potential ef-
fect on metabolizing enzymes and transporters and that
small alterations in VCR concentrations can affect its
clinical efficacy and/or toxicity. As such, in the current
manuscript we are testing the impact of different levels
of plasma lipoproteins concentrations on the dispos-
ition of VCR regarding its plasma levels and protein
binding in a polymer-induced HL rat model.
Methods
Materials and reagents
Vincristine powder (purity >99 %) was purchased from
Selleckchem (Houston, TX, USA). Itraconazole was a
kind gift from (Nifty Labs PVT LTD, Hyderabad, India).
HPLC grade Methanol and acetonitrile (Fisher Scientific
UK Limited, Loughborough, Leicestershire, UK), analytical
grade potassium dihydrogen orthophosphate (Riedel-
de-Haën, Germany) and high purity distilled water were
used. Vinracine® intravenous injection vials labelled to
contain 1 mg/mL vincristine sulphate (EIMC United
Pharmaceuticals, Cairo, Egypt), normal saline and hep-
arin sodium for injection 5000 U/mL were purchased
from the Egyptian market. Aerraine® Isoflurane USP
was also purchased from local market.
Animals and pre-experimental procedures
Experimental protocols involving animals, were approved
by the Ethics Committee, Faculty of Pharmacy, Alexandria
University. Sprague–Dawley rats were used in the studies.
All rats weighed between 150 and 250 g and were housed
in temperature-controlled rooms with 12 h of light per
day. The animals were fed a standard commercial rat
chow containing 4.5 % fat (Tanta Oil and Soap JSC, Tanta,
Egypt). Free access to food and water was permitted prior
to experimentation. Rats were allocated into either nor-
molipidemic (NL), intermediate hyperlipidemic (IHL)
or extreme hyperlipidemic (HL) groups. HL was in-
duced by single intraperitoneal injection of 1 g/kg of
P407 (0.13 g/ml solution in normal saline). To ensure
the proper injection of P407, the animals were lightly
anaesthetized using isoflurane, and then allowed to re-
cover. The rats were prepared for i.v dosing by jugular
vein cannulation. For each rat, a single jugular vein was
catheterized with Silastic Laboratory Tubing (Dow
Corning Corporation, Midland, MI) under isoflurane/O2
anesthesia, administered by anesthetic machine. The can-
nula was filled with locking solution containing 100U/ml
heparin in 0.9 % saline. After implantation, the rats were
transferred to their regular holding cages and allowed free
access to water, but food was withheld overnight so that
drug would be administered in the fasted state. The next
morning, normolipidemic rats were transferred to the
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metabolic cages and dosed with i.v. VCR. The hyperlip-
idemic and intermediate hyperlipidemic groups were
dosed VCR after 36 h and 72 h from the P407 injection,
respectively.
Drug administration and sample collection
The intravenous solution was prepared by diluting
Vinracine® (1 mg/mL) intravenous injection vials with
normal saline to reach a final concentration of 0.1 mg/mL.
Rat groups (n = 5–7 each) received 0.15 mg/kg VCR i.v.
immediately followed by injection of sterile normal saline.
At the time of first sample withdrawal, the first 0.2 mL
volume of blood was discarded. Food was provided to
animals 2 h after the dose administration.
Serial blood samples (0.15–0.25 mL) were collected
using the jugular vein cannula at 0.083, 0.167, 0.333, 0.5,
0.75, 1, 2, 4, 6, 8, 24, 48 and 72 h post dose. Plasma was
separated by centrifugation of the blood at 4000 g for
5 min and transferred into clean glass test tubes. The
samples were kept at −20 °C until assayed.
Protein binding study
The unbound fraction of VCR in plasma was determined
using ultrafiltration (Centrifree®, Amicon, Beverly,
Massachusetts). Blood was obtained from NL, IHL and
HL rats by exsanguination via cardiac puncture. For
IHL and HL rats, blood was collected 72 and 36 h after
i.p. doses of P407, respectively. The blood was centrifuged
at 4000 g for 5 min. The NL, IHL and HL rat plasma were
spiked with VCR methanolic solution to allow for final
concentrations of 1 mg/L. The volume of methanol added
to each tube did not exceed 0.05 % (v/v). Tubes were incu-
bated for 1 h in a 37 °C water bath shaker. A volume of
1 mL of each tube was transferred to an ultrafiltration de-
vice (n = 4), (centrifree®, Millipore, Carrigtwohill, Ireland)
which was then placed in a fixed angle centrifuge rotor
and spun at 2000 g for 10 min at 37 °C. The samples were
then analyzed for VCR concentration. In HL and IHL
VCR protein binding test, the ultrafiltration devices were
preincubated of with 5 % Triton® (X-100) for 12 h to
overcome the binding of drugs and lipids to the filter.
The devices were then used after being rinsed several
times with double-distilled water [11, 21].
Assay
A validated HPLC assay was used for the measurement
of VCR concentrations in plasma and Sorenson sodium
phosphate buffer (pH 7.4) [21]. The validated lower limit
of quantitation was 50 ng/mL based on 0.2 mL plasma
or buffer. For standard curve construction, drug-free
plasma and Sorenson sodium phosphate buffer (pH = 7.4)
were used and spiked with appropriate amounts of VCR.
The calibration curves relating peak area ratio to expected
concentration were highly linear from 50 to 5000 ng/mL
of VCR in NL, IHL, HL plasma and buffer (r2 > 0.997).
Data and statistical analysis
Non-compartmental methods were applied to calculate
the pharmacokinetic parameters. The elimination rate
constant (λz) was calculated by subjecting the plasma
concentrations in the terminal phase to linear regression
analysis. The terminal phase t½ was calculated using the
equation t½ =0.693/λz. The AUC0-∞ was calculated
using the combined log-linear trapezoidal rule from time
0 h postdose to the time of the last measured concentra-
tion, plus the quotient of the last measured concentra-
tion divided by λz. The concentration at time 0 (C0)
after i.v. dosing was estimated by back extrapolation of
the log-linear regression line using the first three mea-
sured plasma concentrations to time. The clearance
(Cl) was calculated as the quotient of dose to AUC0-∞
and the volume of distribution (Vβ) as the quotient of
clearance by λz. Volume of distribution of the central
compartment (Vc) is calculated as the quotient of dose
by Co.
The plasma-unbound fraction was determined by div-
iding the VCR concentration in the filtrate by that mea-
sured in the prefiltered plasma. All compiled data were
reported as mean ± SD, unless otherwise indicated. Sig-
nificance of comparisons of means for the interactions
of lipoprotein status and VCR PK, protein binding were
assessed by one way analysis of variance (ANOVA),
followed by Bonferroni post-hoc analysis (SPSS 22, SPSS
Inc, Chicago, IL, USA). In all cases, the level of signifi-
cance after Bonferroni adjustment was set at p = 0.016.
Results and Discussion
After intravenous administration of 0.15 mg/kg of VCR
to fasted rats, the plasma drug level decreased rapidly
during the first 6–8 h, distribution phase, followed by a
slower rate of decline till 72 h post i.v. with a mean elim-
ination t½ of ~ 14 h (Fig. 1). VCR fast distribution phase
followed by a slower elimination phase was had been
previously described in the literature [1, 8]. A brief rise
in concentration was observed at about 24 h which may
indicate enterohepatic recirculation of the drug [22]. This
was not uniform in all rats, where some rats showed this
increase pattern while others demonstrated a regular
concentration decline pattern (Fig. 2). This was reflected
in the variability of the λz calculated (Table 1). Also it ex-
plains the variability in t½ and weight normalized Vβ
(Table 1). It is worth mentioning that such variability in
the decline in VCR plasma concentrations was consistent
in all lipemic groups (NL, IHL and HL) which might be
attributed to the inter-individual variability among rats.
Inspite of this variability, the observed weight normalized
Cl and Vc values were in complete agreement with those
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previously reported by ZHOU et al. (CL = 0.12 ± 0.08 L/Kg
and Vc = 0.20 ± 0.11 L/h/Kg) (Table 1) [8].
To test for the effect of incremental increase in ele-
vated plasma lipoproteins level on the VCR disposition,
a P407-induced HL rat model was utilized. This HL in-
duction method in rodents is an established method that
is utilized by several research groups [12, 23–26]. It was
first described by Johnston and coworkers [25, 27–29].
The P407 polymer, also known as pluronic F127, exerts
its action through inhibiting plasma lipoprotein lipase
and probably cholesterol 7α hydroxylase [27]. This
model of HL is characterized by rapid onset, low tox-
icity, reversibility and ability to induce atherosclerosis
in rodents with repeated doses [25]. It increased serum
baseline corrected serum lipids in a nearly dose propor-
tional fashion [30]. The maximum increase in lipids
was observed at ~36 h, with most lipids remaining ele-
vated for up to 120–180 h post i.p. dose [30, 31]. P407
was also recently proven to significantly increase serum
leptin and decrease the serum adiponectin concentra-
tions [30]. Most of the research laboratories utilizing
this model start dosing their drugs 36 h post P407 ip
injection and considering in their results that the in-
crease in lipoprotein levels would be considerably
higher than that clinically experienced by humans [14].
A recent publication studied the serum lipoproteins
levels after a single 1 g/Kg ip dose of P407 and sug-
gested the use of the model at time points later than
36 h when the lipoprotein concentrations will be more
similar to those seen in hyperlipidemic patients [30]. As
such, in our current study we have decided to study the
effect of two levels of lipoprotein elevation (36 and
72 h post i.p. injection) on the pharmacokinetics and
protein binding of VCR in rat.
VCR exhibits moderate binding affinity to plasma
proteins [32], this was validated by the current protein
binding results (~81–83 % bound). It showed a relatively
small Vc (~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicat-
ing good tissue distribution (Table 1).
The incremental increase in plasma lipoproteins levels
resulted in no significant change in VCR total unbound
fraction (fu, NL = IHL =HL) indicating the very low bind-
ing affinity of VCR to plasma lipoproteins (Table 1). This
was also reflected by the similarity between C0 and Vc
values among the different lipemic groups (Table 1). HL
was reported to alter few metabolizing enzymes expres-
sion which made it necessary to comapre VCR AUC0-∞
and Cl values among rats with elevated lipoprotein level
Fig. 1 Comparative mean ± SD plasma concentration versus time
curves of 0.15 mg/Kg intravenous vincristine sulphate (VCR)
administrated in normolipidemic (NL), intermediate hyperlipidemic
(IHL) or extreme hyperlipidemic (HL) rat groups
Fig. 2 Plasma concentration versus time curves of 0.15 mg/Kg
intravenous vincristine sulphate (VCR) administrated in normolipidemic
(NL) rats showing two different decline patterns
Table 1 Pharmacokinetic parameters of vincristine sulphate
after intravenous administration of 0.15 mg/kg solution in
normolipidemic (NL), intermediate hyperlipidemic (IHL), and
extreme hyperlipidemic (HL) rats
NL IHL HL
Co (mg/L) 1.03 ± 0.50 0.50 ± 0.29 0.99 ± 0.76
AUC0–∞ (mg.h/L) 4.20 ± 3.23 2.25 ± 0.67 3.72 ± 1.38
λz (h-1) 0.06 ± 0.03 0.03 ± 0.01 0.04 ± 0.03
t ½ (h) 14.6 ± 7.62 30.3 ± 11.6 28.2 ± 18.3
CL/kg (L/h/kg) 0.06 ± 0.04 0.07 ± 0.02 0.05 ± 0.02
Vβ/kg (L/kg) 1.53 ± 1.80 2.88 ± 0.52 1.74 ± 1.15
Vc/kg (L/kg) 0.17 ± 0.08 0.39 ± 0.21 0.27 ± 0.22
fu 0.17 ± 0.04 0.19 ± 0.01 0.19 ± 0.07
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[11, 12, 16, 33]. Since VCR is an intermediate to low ex-
traction ratio drug, it is expected that any slight change in
the CYP P450 expression or VCR unbound fraction would
result in a significant alteration of its hepatic clearance.
However, in the current poloxamer-induced HL rat
model, the incremental increase in plasma lipoproteins
levels resulted in no significant change in VCR AUC0-∞
or weight normalized Cl among the different lipemic
groups (Table 1 and Fig. 1). The results also show an
increasing trend in t½ and weight normalized Vβ ac-
companying the increase in the lipid levels however,
this was not statistically significant due to the variabil-
ity in λz (Table 1).
Such results carries good information for ALL, malig-
nant lymphoma and allogenic hematopoietic stem cell
transplantation patients whom plasma lipoprotein levels
were reported to increase during their therapy [19, 20].
It provides initial evidence that VCR does not have high
binding affinity to plasma lipoproteins as such its un-
bound fraction, Co, as well as tissue distribution will not
be highly affected by the transient elevation in the triglyc-
erides levels reported. This would ensure less probability
of VCR concentration based side effects, neurotoxicity,
and better clinical efficiency due to proper tissue distribu-
tion [1, 3, 6]. VCR is eliminated mainly in bile and is me-
tabolized through CYP 3A4 and 3A5 enzymes [1]. Drugs
or diseases that affect those two elimination mechanisms
through competitive or functional inhibition are expected
to increase the VCR exposure in patients and increase its
peripheral and/or central neurotoxic effect [3, 34]. It is
worth mentioning, that VCR central neurotoxicity, sei-
zures, results from SIADH leading to hyponatremia
and currently researchers are investigating methods for
prophylaxis and treatment of such toxicity [1, 4, 35, 36]. It
is also important to mention that common genetic poly-
morphisms in CYP3A5 expression may contribute to the
interpatient variability in VCR elimination [3]. In our HL
induced rodent model we report no drug-disease inter-
action between elevated plasma lipoproteins and VCR
elimination as such its exposure (AUC0-∞) and elimination
phase t½ were not altered. However, it is important to
note that the patient population we are targeting are usu-
ally exposed to complex drug regimens and exhibit modu-
lated drug response. As such, despite HL by itself did not
modulate VCR disposition, it could potentiate another
drug-drug or drug-disease interaction involving VCR
which warrants further study and monitoring.
Conclusion
In conclusion, VCR demonstrated low affinity binding to
plasma lipoproteins as such the incremental increase in
plasma lipoprotein levels resulted in no significant alter-
ations in VCR unbound fraction, initial plasma concen-
trations and volume of distribution. Induced HL also did
not affect VCR elimination where similar VCR exposure
(AUC0-∞) and elimination phase t½ were reported along
the different lipemic groups. As such, ALL, malignant
lymphoma and allogenic hematopoietic stem cell trans-
plantation patients whom plasma triglycerides levels
were reported to increase during therapy need not worry
about HL-VCR interaction. Whether, HL can potentiate
another drug-drug or drug-disease interaction involving
VCR warrants further studying and monitoring to ensure
therapeutic safety and efficiency in such immunocom-
promised population.
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